Ginkgo Bioworks Reports 49% Revenue Decline and $82.6 Million Net Loss in Q1 2026

Ginkgo Bioworks Holdings, Inc. reported a significant decline in revenue for the first quarter of 2026, generating $19.5 million compared to $38.2 million in the same period of 2025, marking a decrease of approximately 49%. This decline was attributed primarily to the recognition of $7.5 million in non-cash revenue from a previously deferred revenue balance related to a terminated contract with BiomEdit in the first quarter of 2025, as well as a reduction in services provided to a major customer in the agriculture sector. The company also reported a net loss of $82.6 million for the quarter, a slight improvement from the $90.9 million loss recorded in the prior year.

In terms of operational efficiency, Ginkgo Bioworks has made strides in reducing its operating expenses, which totaled $90.8 million for the first quarter of 2026, down from $119.2 million in the same period last year. This reduction was driven by lower research and development costs, which fell to $49.9 million from $70.9 million, and a decrease in general and administrative expenses, which dropped to $37.8 million from $39.7 million. The company did not incur any restructuring charges in the latest quarter, a notable change from the $4.5 million recorded in the first quarter of 2025.

Ginkgo Bioworks has also undergone strategic changes, including the divestiture of its Biosecurity business, which was completed on April 3, 2026. This divestiture is expected to significantly impact the company's operations and financial results moving forward. The company has classified the financial results of the Biosecurity business as discontinued operations in its financial statements. As of March 31, 2026, Ginkgo reported total assets of $1.03 billion, down from $1.12 billion at the end of 2025, with cash and cash equivalents decreasing to $143.9 million from $167.2 million.

The company’s workforce has also seen changes, with a reduction in employee headcount as part of its restructuring efforts initiated in 2024. Ginkgo Bioworks continues to focus on its core mission of making biology easier to engineer, offering biological R&D services and tools across various industries. Looking ahead, the company anticipates that its expenditures will exceed revenue for at least the next 12 months as it continues to invest in research and development and expand its tools offerings. Ginkgo has indicated that it expects to maintain sufficient liquidity to fund its operations through this period, with cash and marketable securities totaling $373.5 million as of March 31, 2026.